Corporate Profile

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.

Recent Press Releases

November 18, 2014 - 10:08 a.m.
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4Printer Friendly Version 

Upcoming Events

Tuesday, December 2, 2014 11:15 a.m. ET
31st NASDAQ Investor Program
LocationLondon, UK
Wednesday, December 3, 2014 9:30 a.m. ET
26th Annual Piper Jaffray Healthcare Conference
LocationNew York, NY
Saturday, December 6, 2014 through Tuesday, December 9, 2014
American Society of Hematology (ASH)
LocationSan Francisco, CA

Most Viewed Links

Updated 10/14/14
1.Stock Information
2.SEC Filings
3.Earnings
4.U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
5.Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection
* Data collected 10/06/14 - 10/13/14

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
NASDAQ (US Dollar)
$100.58
 Stock is Down 0.01 (0.01%)
Data as of 11/21/14 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Q3 2014 Gilead Sciences Earnings Conference Call

October 28, 2014 4:30 p.m. ET
Play